AUG 0 6 2001 Linereb to: Horeb

Patent Application Attorney Docket No.PC10834ATMC

hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addresse to: Hon. Commissioner for Patents, Box DD-Washington, D.C. 20231 on this 2nd day of August, 2001. By (Signature of person mailing) Jeanine M. Herrera (Typed or printed name of person) IN THE UNITED STATES PATENT AND TRADEMARK OFFICE John R. Hadcock IN RE APPLICATION OF: Examiner: To be assigned APPLICATION NO.: 09/841,276 Group Art Unit: To be assigned April 24, 2001 FILING DATE: TITLE: Methods of Treating Obesity Using a Neurotensin: Receptor Ligand Commissioner for Patents

Sir:

Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820, which lists the references, cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.204(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

No fee is believed to be due. However, should a fee be deemed required, the Commissioner is hereby authorized to charge any fees in connection with this paper to Deposit Account No. 16-1445.

Date: 8/2/2001

Respectfully submitted,

Todd M. Crissey

Attorney for Applicant(s)

Reg. No. 37,807

Pfizer Inc.
Patent Department, MS 4159
Eastern Point Road
Groton, Connecticut 06340
(860) 715-4331